RILEPTID AND RISPOLEPT FOR TREATMENT OF PSYCHOTIC DISORDERS OF SCHIZOPHRENIA SPECTRUM: AN OPEN, COMPARATIVE, NON-RANDOMIZED, PROSPECTIVE TRIAL
This trial was directed at a comparative study of efficacy of drugs Rispolept and Rileptid for the purpose of revealing the significant differences according to parameters of clinical efficacy and safety at the hospital treatment stage followed by introduction into practice. Clinical-psychopathological and psychometrical examination of 60 patients with psychotic schizophrenia spectrum disorders has been carried out. Group 1 (40 patients) received Rispolept, group 2 (20 patients) received Rileptid. Investigation did not yield statistically significant differences between groups according to parameters of efficacy and safety during treatment of schizophrenia spectrum disorders of psychotic level (p>0.05).